GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organogenesis Holdings Inc (NAS:ORGO) » Definitions » Price-to-Free-Cash-Flow

Organogenesis Holdings (Organogenesis Holdings) Price-to-Free-Cash-Flow : 46.63 (As of Apr. 26, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Organogenesis Holdings Price-to-Free-Cash-Flow?

As of today (2024-04-26), Organogenesis Holdings's share price is $2.285. Organogenesis Holdings's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.05. Hence, Organogenesis Holdings's Price-to-Free-Cash-Flow Ratio for today is 46.63.

The historical rank and industry rank for Organogenesis Holdings's Price-to-Free-Cash-Flow or its related term are showing as below:

ORGO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 18.8   Med: 55.11   Max: 3262.86
Current: 46.47

During the past 9 years, Organogenesis Holdings's highest Price-to-Free-Cash-Flow Ratio was 3262.86. The lowest was 18.80. And the median was 55.11.

ORGO's Price-to-Free-Cash-Flow is ranked worse than
79.15% of 494 companies
in the Drug Manufacturers industry
Industry Median: 21.73 vs ORGO: 46.47

Organogenesis Holdings's Free Cash Flow per Share for the three months ended in Dec. 2023 was $0.06. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.05.

During the past 9 years, Organogenesis Holdings's highest 3-Year average Free Cash Flow per Share Growth Rate was 45.80% per year. The lowest was -62.90% per year. And the median was -5.80% per year.


Organogenesis Holdings Price-to-Free-Cash-Flow Historical Data

The historical data trend for Organogenesis Holdings's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organogenesis Holdings Price-to-Free-Cash-Flow Chart

Organogenesis Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only - - 40.17 - 83.47

Organogenesis Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 83.47

Competitive Comparison of Organogenesis Holdings's Price-to-Free-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organogenesis Holdings's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Organogenesis Holdings's Price-to-Free-Cash-Flow falls into.



Organogenesis Holdings Price-to-Free-Cash-Flow Calculation

Organogenesis Holdings's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=2.285/0.049
=46.63

Organogenesis Holdings's Share Price of today is $2.285.
Organogenesis Holdings's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.05.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Organogenesis Holdings  (NAS:ORGO) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Organogenesis Holdings Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Organogenesis Holdings's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Organogenesis Holdings (Organogenesis Holdings) Business Description

Traded in Other Exchanges
Address
85 Dan Road, Canton, MA, USA, 02021
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.
Executives
Albert Erani 10 percent owner 150 DAN ROAD, 150 DAN ROAD, CANTON MA 01002
Michael W Katz 10 percent owner
Arthur S Leibowitz director 139 SOUNDVIEW DRIVE, PORT WASHINGTON NY 11050
Michael Joseph Driscoll director C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gary S. Gillheeney director, officer: President and CEO C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gilberto Quintero director C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Michele Ilene Korfin director 17 STATE STREET, 7TH FLOOR, NEW YORK NY 10004
Antonio S. Montecalvo officer: VP Health Policy & Contracting C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Jon L Giacomin director 7000 CARDINAL PLACE, DUBLIN OH 43017
David Francisco officer: Chief Financial Officer C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Red Holdings, Llc 10 percent owner C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Prathyusha Duraibabu director C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND CA 94804
Glenn H Nussdorf director, 10 percent owner
Alan A. Ades director, 10 percent owner C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gn 2016 Organo 10-year Grat U/a/d September 30, 2016 10 percent owner C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021

Organogenesis Holdings (Organogenesis Holdings) Headlines

From GuruFocus

Should Investors Worry About Organogenesis Holdings Inc's Insider Sells?

By GuruFocus Research GuruFocus Editor 05-18-2022